Jos Jansen

5 117 Screening for abnormal glycosylation in a cohort of adult liver disease patients Table 1. Patient characteristics tIEF selected samples (n=961) QTOF-MS selected samples (n=149) LTx (n=511) CLD (n=450) LTx (n=76) CLD (n=34) HC (n=39) Mean age (years) 48.5 (SD 12.2) 50.0 (SD 15.5) 52.6 (SD 12.0) 51.8 (SD 13.2) 47.1 (SD 14.2) Male sex 283 (55.4%) 211 (46.9%) 50 (65.8%) 15 (44.1%) 21 (53.8%) Etiology Acute liver failure 38 (7.4%) 2 (0.4%) 1 (1.3%) 0 n.a. Alcohol liver disease 121 (23.7%) 20 (4.4%) 35 (46.1%) 6 (17.6%) n.a. Auto-immune hepatitis 39 (7.6%) 152 (33.8%) 3 (3.9%) 15 (44.1%) n.a. Cholestatic liver disease 157 (30.7%) 42 (9.3%) 11 (14.5%) 0 n.a. Cryptogenic cirrhosis 54 (10.6%) 20 (4.4%) 10 (13.2%) 1 (2.9%) n.a. Metabolic disease 26 (5.1%) 7 (1.6%) 7 (9.2%) 0 n.a. NASH 10 (2.0%) 36 (8.0%) 0 3 (8.8%) n.a. Other 61 (11.9%) 36 (8.0%) 8 (10.5%) 2 (5.9%) n.a. Unknown 5 (1.0%) 5 (1.1%) 1 (1.3%) 0 n.a. Gilbert - 25 (5.6%) 0 2 (5.9%) n.a. Viral hepatitis - 94 (20.9%) 0 5 (14.7%) n.a. DILI - 11 (2.4%) 0 0 n.a. LTx = Liver transplant recipient, CLD = Chronic liver disease, NASH = non-alcoholic steatohepatitis, DILI = drug induced liver injury. HC = healthy controls, SD= standard deviation, n.a. = not applicable